Stem cells enhance reperfusion following ischemia: Validation using laser speckle imaging in predicting tissue repair

Tang, Ya Hui; Thompson, RoxAnna; Nathan, Cherie‐Ann O.; Alexander, J. Steven; Lian, Timothy

doi:10.1002/lary.27110

Cited by 6 publications

(7 citation statements)

References 53 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine the extent of hPMSCs ability to preserve CBF at 24 h after IP-SCT in the MCAO mice, we measured cerebral perfusion using Laser Speckle Contrast Imaging [36]. There was significant preservation of CBF in our hPMSC-treated group (9.657 § 0.85 vs 3.24 § 0.72 in untreated post-MCAO) (p = 0.0001; Fig.…”

Section: Ip Injection Of Hpmscs Preserves Ipsilateral Hemisphere Viability and Perfusion In The Mcao Modelmentioning

confidence: 83%

Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated preservation of cerebral blood flow

et al. 2021

View full text Add to dashboard Cite

Background Besides long-term trans-differentiation into neural cells, benefits of stem cell therapy (SCT) in ischemic stroke may include secretion of protective factors, which partly reflects extracellular vesicle (EVs) released by stem cell. However, the mechanism(s) by which stem cells/EVs limit stroke injury have yet to be fully defined. Methods We evaluated the protection effect of human placenta mesenchymal stem cells (hPMSC) as a potential form of SCT in experimental ischemic stroke ‘transient middle cerebral artery occusion (MCAO)/reperfusion’ mice model. Findings We found for the first time that intraperitoneal administration of hPMSCs or intravenous hPMSC-derived EVs, given at the time of reperfusion, significantly protected the ipsilateral hemisphere from ischemic injury. This protection was associated with significant restoration of normal blood flow to the post-MCAO brain. More importantly, EVs derived from hPMSC promote paracrine-based protection of SCT in the MCAO model in a cholesterol/lipid-dependent manner. Interpretation Together, our results demonstrated beneficial effects of hPMSC/EVs in experimental stroke models which could permit the rapid “translation” of these cells into clinical trials in the near-term.

show abstract

Section: Ip Injection Of Hpmscs Preserves Ipsilateral Hemisphere Viability and Perfusion In The Mcao Modelmentioning

confidence: 83%

Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated preservation of cerebral blood flow

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Next, to determine whether and to what extent MLN‐treated hPMSC might affect CBF compared to untreated hPMSC following MCAO‐induced strokes, we measured cerebral perfusion using Laser Speckle Contrast Imaging 26 . We found that total CBF was significantly reduced in MLN‐hPMSCs treated MCAO mice (6.25 ± 0.45, P < .0001) compared to hPMSC‐treated MCAO (10.99 ± 0.66) and sham groups (13.42 ± 1.01, P < .0001; Figure 2A) similar to untreated MCAO mice.…”

Section: Resultsmentioning

confidence: 99%

Human Placenta Mesenchymal Stem Cell Protection in Ischemic Stroke is Angiotensin Converting Enzyme-2 and Masr Receptor-Dependent

et al. 2021

View full text Add to dashboard Cite

Thromboembolic stroke remains a major cause of neurological disability and death. Current stroke treatments (aspirin, tissue plasminogen activator) are significantly limited by timing and risks for hemorrhage which have driven researchers to explore other approaches. Stem cell-based therapy appears to be an effective option for ischemic stroke. Besides trans-differentiation into neural cells, stem cells also provide acute protection via paracrine signaling pathways through which releasing neuroprotective factors. We previously reported that intraperitoneal administration of human placenta mesenchymal stem cell (hPMSC) therapy upon reperfusion significantly protected the brain against middle cerebral artery occlusion (MCAO)-induced injury. In the present study, we specifically investigated the role of hPMSC-derived angiotensin converting enzyme-2 (ACE-2) in protection of MCAO-induced brain injury by measurement of brain tissue viability, cerebral blood flow, and neurological score. Here, we report for the first time that hPMSC expressing substantial amount of ACE-2, which mediates hPMSC protection in the MCAO model. Strikingly, we found that the protective effects of hPMSC in MCAO-induced brain injury could be attenuated by pretreatment of hPMSCs with MLN-4760, a specific inhibitor of ACE-2 activity, or by transfection of hPMSCs with ACE-2-shRNA-lentivirus. The hPMSC-derived ACE-2 specific protective mechanism was further demonstrated by administration of PD123319, an Angiotensin type-2 receptor antagonist, or A779, a MasR antagonist. Importantly, our study demonstrated that the protective effects of hPMSC in experimental stroke are ACE-2/MasR dependent and this signaling pathway represents an innovative and highly promising approach for targeted stroke therapy.

show abstract

“…The MSCs show chemotaxis in vitro by the Stromal Cell-Derived Factor (SDF1), Platelet-Derived Growth Factor (PDGF), Insulin-Like Growth Factor-1, Interleukin-8 (IL-8) and Tumor Necrosis Factor-α (TNFα). In murine models, the MSCs used in the systemic administration are capable of getting into the damaged tissues [14,34,36].…”

Section: Discussionmentioning

confidence: 99%

“…The ADSCs are able to protect axial flaps from the IRI with results as satisfactory as the ones obtained in procedures without ischemia, because of the improvement in the angiogenic response and the blood perfusion elevation [10]. Many studies use the ADSCs to prevent ischemic injuries in skin flaps [7][8][9][10][11][12][13][14], as others [15,16] used them to improve the quality of skin grafts.…”

Section: Journal Of Head Neck and Spine Surgerymentioning

confidence: 99%

See 1 more Smart Citation

Stem Cells to Improve the Wound Healing

Vidor¹,

Contesini²

2018

JHNSS

View full text Add to dashboard Cite

The cellular therapy using Mesenchymal Stem Cells, specially its two subtypes -Bone-marrow Mesenchymal Stem Cells and Adipose Derived Stem Cells -can benefit by virtue of the possibility of differentiating in specialized cells that secrete and suppress growing factors and cytokines necessary in the lesion niche. When attracted by the pro-inflammatory sinalization of the lesion, they act using the paracrine signaling, decreasing the inflammation, increasing the angiogenesis and the cell migration and proliferation. The development in the researches regarding the association of the application of MSCs, with reconstructive surgery practices, leads to effective future results that can bring more benefits to the clinic practice of this field. This paper has the objective of briefly reviewing the literature about the usage of MSCs and its subtypes, the ADSCs, to improve the skin cicatrization.

show abstract

Stem cells enhance reperfusion following ischemia: Validation using laser speckle imaging in predicting tissue repair

Abstract: NA. Laryngoscope, 128:E198-E205, 2018.

Cited by 6 publications

References 53 publications

Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated preservation of cerebral blood flow

Human placental mesenchymal stem cells improve stroke outcomes via extracellular vesicles-mediated preservation of cerebral blood flow

Human Placenta Mesenchymal Stem Cell Protection in Ischemic Stroke is Angiotensin Converting Enzyme-2 and Masr Receptor-Dependent

Stem Cells to Improve the Wound Healing

Contact Info

Product

Resources

About